Otros idiomas Sinopharm Group Co. Ltd.

Acciones

1099

CNE100000FN7

Mercado cerrado - Hong Kong S.E. Otros sitios de cotización 10:08:20 26/04/2024			Varia. Cinco días.	Varia. 1 de enero.
21,55 ^HKD	-0,92 %		+8,40 %	+5,38 %

26/04	El banco central y las perspectivas tecnológicas elevan las principales bolsas asiáticas	MT
10/04	La FDA china concede la aprobación de comercialización a las materias primas farmacéuticas de la filial de Shyndec	MT

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Central Bank, Tech Outlooks Lift Major Asian Stock Markets	26/04
Borse Cina : chiudono miste, in rialzo Hong Kong con decisione su tassi	22/04
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	16/04
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	10/04
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	27/03
Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue	25/03
Sinopharm Group Co. Ltd. Proposes Final Dividend of for the Financial Year Ended 31 December 2023, Payable on 13 August 2024	24/03
Sinopharm Group Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	24/03
China Stocks Muted at Close as Recovery Optimism Fades; Sinopharm Jumps 6% on Upbeat 2023 Earnings	21/03
Sinopharm's 2023 Profit Climbs 9%; Shares Up 6%	21/03
US Inflation, Light News Flow Churns Asian Stock Markets	13/03
Sinopharm Group Co. Ltd. Announces Change of Registered Address	12/03
China Traditional Chinese Medicine's Stock Bolts on Privatization Offer	22/02
China stocks extend gains led by coal, AI; HK shares up	22/02
Hong Kong Stocks Hover Near Two-Month Highs Amid Mixed Corporate Earnings	22/02
China stocks jump with AI shares leading on Nvidia forecast; HK shares flat	22/02
Sinopharm offers to take China-TCM private in nearly $3 bln deal	21/02
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	21/02
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	20/02
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	03/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Sinopharm Group Co. Ltd.

Acciones

1099

CNE100000FN7

Otros idiomas

Filtros